Home » Topics » BioWorld Science

BioWorld Science
RSS

Takeda starts enrollment in first-in-human trial of TAK-102

Aug. 21, 2020

Genmab initiates first-in-human study of GEN-1044

Aug. 21, 2020

Esteve presents dual sigma1 and mu-opioid receptor ligands

Aug. 21, 2020

New opioid receptor ligands identified at Yangtze River Pharmaceutical

Aug. 21, 2020

Jiangsu Chia Tai Tianqing Pharmaceutical discovers HBV capsid assembly inhibitors

Aug. 21, 2020

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent ADORA2A/B antagonists

Aug. 21, 2020

Phosphodiesterase PDE3A and PDE3B inhibitors described by Bayer, The Broad Institute

Aug. 21, 2020

Promising preclinical data for novel lymph node targeting COVID-19 vaccine

Aug. 21, 2020

ORIC Pharmaceuticals' OP-4954 displays selective glucocorticoid receptor antagonism

Aug. 21, 2020

Another obstacle to universal flu vaccine

Aug. 21, 2020

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...